Cambridge Investment Research Advisors Inc. Grows Stake in Kenvue Inc. (NYSE:KVUE)

Cambridge Investment Research Advisors Inc. increased its holdings in Kenvue Inc. (NYSE:KVUE) by 3.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,864 shares of the company’s stock after purchasing an additional 2,373 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Kenvue were worth $1,470,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Manchester Capital Management LLC lifted its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares in the last quarter. Pacific Capital Wealth Advisors Inc. bought a new stake in Kenvue in the 4th quarter valued at $28,000. Mather Group LLC. purchased a new stake in Kenvue in the 1st quarter worth $28,000. Riverview Trust Co bought a new position in shares of Kenvue during the 1st quarter valued at about $33,000. Finally, MV Capital Management Inc. grew its position in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KVUE. HSBC boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. UBS Group increased their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Citigroup reduced their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Price Performance

KVUE stock opened at $22.10 on Wednesday. The stock has a market cap of $42.32 billion, a PE ratio of 28.33, a P/E/G ratio of 2.76 and a beta of 1.38. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $22.98. The company has a 50-day moving average price of $19.67 and a 200 day moving average price of $19.60. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. Equities research analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.71%. The ex-dividend date was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio is 105.13%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.